Cost-Effectiveness Analysis of Evolocumab Therapy in Patients at High Risk of Cardiovascular Events in the Context of the Brazilian Unified Health System.

MLA

Latado, Luiza, et al. “Cost-Effectiveness Analysis of Evolocumab Therapy in Patients at High Risk of Cardiovascular Events in the Context of the Brazilian Unified Health System.” Arquivos Brasileiros de Cardiologia, vol. 117, no. 5, Nov. 2021, pp. 988–96. EBSCOhost, https://doi.org/10.36660/abc.20200690.

APA

Latado, L., Melo, R. M. V. de, Mistro, S., Latado, A. L., Nascimento, H. F. do, Lira, Y. M., Oliveira, N. F. C. de, Galindo, Y. de S., Viana, T., & Passos, L. C. S. (2021). Cost-Effectiveness Analysis of Evolocumab Therapy in Patients at High Risk of Cardiovascular Events in the Context of the Brazilian Unified Health System. Arquivos Brasileiros de Cardiologia, 117(5), 988–996. https://doi.org/10.36660/abc.20200690

Chicago

Latado, Luiza, Rodrigo Morel Vieira de Melo, Sóstenes Mistro, Adriana Lopes Latado, Harrison Floriano do Nascimento, Yasmin Menezes Lira, Natalia Ferreira Cardoso de Oliveira, Yuri de Santana Galindo, Tainá Viana, and Luiz Carlos Santana Passos. 2021. “Cost-Effectiveness Analysis of Evolocumab Therapy in Patients at High Risk of Cardiovascular Events in the Context of the Brazilian Unified Health System.” Arquivos Brasileiros de Cardiologia 117 (5): 988–96. doi:10.36660/abc.20200690.